GSK256073, a selective agonist of G-protein coupled receptor 109A (GPR109A) reduces serum glucose in subjects with type 2 diabetes mellitus

Diabetes, Obesity and Metabolism

Volumn 15, Issue 11, 2013, Pages 1013-1021

  Dobbins, R L ^a   Shearn, S P ^a   Byerly, R L ^a   Gao, F F ^a   Mahar, K M ^a   Napolitano, A ^b   Nachbaur, G J ^c   Le Monnier de Gouville, A C ^c  

^a GLAXOSMITHKLINE   (United States)

^b GLAXOSMITHKLINE   (United Kingdom)

^c GLAXOSMITHKLINE   (France)

Author keywords

Clinical trial; GPR109A; GSK256073; HM74A; Niacin receptor

Indexed keywords

ANTIDIABETIC AGENT; C PEPTIDE; FATTY ACID; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR 109A; GLUCOSE; GLYCEROL; GSK 256073; INSULIN; PLACEBO; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIDIABETIC ACTIVITY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; ERYTHEMA; FATTY ACID BLOOD LEVEL; FEMALE; FLUSHING; GLUCOSE HOMEOSTASIS; GLYCEROL BLOOD LEVEL; HEART RATE; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; LIPOLYSIS; MALE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN BLOOD LEVEL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE BLIND PROCEDURE; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

CLINICAL TRIAL; GPR109A; GSK256073; HM74A; NIACIN RECEPTOR;

C-PEPTIDE; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUGS, INVESTIGATIONAL; FATTY ACIDS, NONESTERIFIED; FEMALE; FOLLOW-UP STUDIES; GLYCEROL; HUMANS; HYPERGLYCEMIA; HYPERINSULINISM; HYPOGLYCEMIC AGENTS; HYPOLIPIDEMIC AGENTS; INSULIN RESISTANCE; MALE; MIDDLE AGED; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, NICOTINIC; SINGLE-BLIND METHOD;

EID: 84885313597     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12132     Document Type: Article

References (36)

1. Baldeweg SE, Golay A, Natali A, Balkau B, Del PS, Coppack SW. Insulin resistance, lipid and fatty acid concentrations in 867 healthy Europeans. European Group for the Study of Insulin Resistance (EGIR). Eur J Clin Invest 2000; 30: 45-52.
2. Paolisso G, Tataranni PA, Foley JE, Bogardus C, Howard BV, Ravussin E. A high concentration of fasting plasma non-esterified fatty acids is a risk factor for the development of NIDDM. Diabetologia 1995; 38: 1213-1217.
3. McGarry JD. Banting lecture 2001: dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. Diabetes 2002; 51: 7-18.
4. Randle PJ, Garland PB, Hales CN, Newsholme EA. The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1963; 1: 785-789.
5. Reaven GM, Hollenbeck C, Jeng CY, Wu MS, Chen YD. Measurement of plasma glucose, free fatty acid, lactate, and insulin for 24h in patients with NIDDM. Diabetes 1988; 37: 1020-1024.
6. Shulman GI. Cellular mechanisms of insulin resistance. J Clin Invest 2000; 106: 171-176.
7. Boden G, Chen X. Effects of fat on glucose uptake and utilization in patients with non-insulin-dependent diabetes. J Clin Invest 1995; 96: 1261-1268.
8. Ferrannini E, Barrett EJ, Bevilacqua S, DeFronzo RA. Effect of fatty acids on glucose production and utilization in man. J Clin Invest 1983; 72: 1737-1747.
9. Hawkins M, Tonelli J, Kishore P et al. Contribution of elevated free fatty acid levels to the lack of glucose effectiveness in type 2 diabetes. Diabetes 2003; 52: 2748-2758.
10. Bajaj M, Suraamornkul S, Romanelli A et al. Effect of a sustained reduction in plasma free fatty acid concentration on intramuscular long-chain fatty Acyl-CoAs and insulin action in type 2 diabetic patients. Diabetes 2005; 54: 3148-3153.
11. Santomauro AT, Boden G, Silva ME et al. Overnight lowering of free fatty acids with Acipimox improves insulin resistance and glucose tolerance in obese diabetic and nondiabetic subjects. Diabetes 1999; 48: 1836-1841.
12. Worm D, Henriksen JE, Vaag A, Thye-Ronn P, Melander A, Beck-Nielsen H. Pronounced blood glucose-lowering effect of the antilipolytic drug acipimox in noninsulin-dependent diabetes mellitus patients during a 3-day intensified treatment period. J Clin Endocrinol Metab 1994; 78: 717-721.
13. Lavezzari M, Milanesi G, Oggioni E, Pamparana F. Results of a phase IV study carried out with acipimox in type II diabetic patients with concomitant hyperlipoproteinaemia. J Int Med Res 1989; 17: 373-380.
14. Vaag AA, Beck-Nielsen H. Effects of prolonged Acipimox treatment on glucose and lipid metabolism and on in vivo insulin sensitivity in patients with non-insulin dependent diabetes mellitus. Acta Endocrinol (Copenh) 1992; 127: 344-350.
15. Karpe F, Frayn KN. The nicotinic acid receptor-a new mechanism for an old drug. Lancet 2004; 363: 1892-1894.
16. Tunaru S, Kero J, Schaub A et al. PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect. Nat Med 2003; 9: 352-355.
17. Wise A, Foord SM, Fraser NJ et al. Molecular identification of high and low affinity receptors for nicotinic acid. J Biol Chem 2003; 278: 9869-9874.
18. Fuccella LM, Goldaniga G, Lovisolo P et al. Inhibition of lipolysis by nicotinic acid and by acipimox. Clin Pharmacol Ther 1980; 28: 790-795.
19. Martres P. HM74a agonists: will they be the new generation of nicotinic acid? Curr Top Med Chem 2009; 9: 428-435.
20. Vosper H. Niacin: a re-emerging pharmaceutical for the treatment of dyslipidaemia. Br J Pharmacol 2009; 158: 429-441.
21. Wilson PW, Grundy SM. The metabolic syndrome: practical guide to origins and treatment: Part I. Circulation 2003; 108: 1422-1424.
22. Mahar Doan KM, Olson EJ, Haws TF, Gao F, Fossler MJ. Model based, adaptive study design allowed early termination during POM/POC study. J Clin Pharmacol 2010 Ref Type: Abstract; 50: 1072.
23. Levy JC, Matthews DR, Hermans MP. Correct homeostasis model assessment (HOMA) evaluation uses the computer program. Diabetes Care 1998; 21: 2191-2192.
24. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
25. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care 2004; 27: 1487-1495.
26. Roden M, Stingl H, Chandramouli V et al. Effects of free fatty acid elevation on postabsorptive endogenous glucose production and gluconeogenesis in humans. Diabetes 2000; 49: 701-707.
27. Landau BR. Glycerol production and utilization measured using stable isotopes. Proc Nutr Soc 1999; 58: 973-978.
28. Cusi K, Kashyap S, Gastaldelli A, Bajaj M, Cersosimo E. Effects on insulin secretion and insulin action of a 48-h reduction of plasma free fatty acids with acipimox in nondiabetic subjects genetically predisposed to type 2 diabetes. Am J Physiol Endocrinol Metab 2007; 292: E1775-E1781.
29. Seck T, Nauck M, Sheng D et al. Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study. Int J Clin Pract 2010; 64: 562-576.
30. Saloranta C, Groop L, Ekstrand A, Franssila-Kallunki A, Eriksson J, Taskinen MR. Different acute and chronic effects of acipimox treatment on glucose and lipid metabolism in patients with type 2 diabetes. Diabet Med 1993; 10: 950-957.
31. Saloranta C, Taskinen MR, Widen E, Harkonen M, Melander A, Groop L. Metabolic consequences of sustained suppression of free fatty acids by acipimox in patients with NIDDM. Diabetes 1993; 42: 1559-1566.
32. Garg A, Grundy SM. Nicotinic acid as therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. JAMA 1990; 264: 723-726.
33. Grundy SM, Vega GL, McGovern ME et al. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. Arch Intern Med 2002; 162: 1568-1576.
34. Kok P, Buijs MM, Kok SW et al. Acipimox enhances spontaneous growth hormone secretion in obese women. Am J Physiol Regul Integr Comp Physiol 2004; 286: R693-R698.
35. Salgin B, Marcovecchio ML, Humphreys SM et al. Effects of prolonged fasting and sustained lipolysis on insulin secretion and insulin sensitivity in normal subjects. Am J Physiol Endocrinol Metab 2009; 296: E454-E461.
36. Lauring B, Taggart AK, Tata JR et al. Niacin lipid efficacy is independent of both the niacin receptor GPR109A and free fatty acid suppression. Sci Transl Med 2012; 4: 148ra115.